This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albanell, J. Articles by Baselga, J. Search for Related Content PubMed PubMed Citation Articles by Albanell, J. Articles by Baselga, J. Social Bookmarking                            What's this?

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

From the Oncology Service, Vall d’Hebron University Hospital; Dermatology Service, Hospital Clinic; Transfusio i Banc de Teixits, Vall d’Hebron Vall d’Hebron University Hospital, Barcelona, Spain; AstraZeneca Pharmaceuticals, Wilmington, DE; Oncology Service, M.D. Anderson Cancer Center, Houston, TX; Oncology Service, Harper Hospital, Detroit, MI; AstraZeneca Pharmaceuticals, Alderley Park; Department of Pharmacology, Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; and Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia.

Address reprint requests to Jose Baselga, MD, Oncology Service, Vall d’Hebron University Hospital, Paseo Vall d’Hebron 119-129, Barcelona 08035, Spain; email: baselga{at}hg.vhebron.es

PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa; AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom) is under development as an anticancer agent. We studied the pharmacodynamic effects of ZD1839 on EGFR in the skin, an EGFR-dependent tissue, in cancer patients participating in ZD1839 phase I clinical trials.

PATIENTS AND METHODS: We studied 104 pre– and/or on–ZD1839 therapy ( at day 28 of therapy) skin biopsies from 65 patients receiving escalating doses of daily oral ZD1839. We measured ZD1839 effects on EGFR activation by immunohistochemistry using an antibody specific for the activated (phosphorylated) EGFR. Effects on receptor signaling (activated mitogen-activated protein kinase [MAPK]), proliferation, p27^KIP1, and maturation were also assessed.

RESULTS: Histopathologically, the stratum corneum of the epidermis was thinner during therapy (P < .001). In hair follicles, prominent keratin plugs and microorganisms were found in dilated infundibula. ZD1839 suppressed EGFR phosphorylation in all EGFR-expressing cells (P < .001). In addition, ZD1839 inhibited MAPK activation (P < .001) and reduced keratinocyte proliferation index (P < .001). Concomitantly, ZD1839 increased the expression of p27^KIP1 (P < .001) and maturation markers (P < .001) and increased apoptosis (P < .001). These effects were observed at all dose levels, before reaching dose-limiting toxicities.

CONCLUSION: ZD1839 inhibits EGFR activation and affects downstream receptor-dependent processes in vivo. These effects were profound at doses well below the one producing unacceptable toxicity, a finding that strongly supports pharmacodynamic assessments to select optimal doses instead of a maximum-tolerated dose for definitive efficacy and safety trials.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Mori, Y. Ohno, F. Ito, N. Funaguchi, K. Yanase, J. Endo, M. Nakano, B. L. Bai La, and S. Minatoguchi Massive Hematuria from the Bilateral Upper Urinary Tract in a Patient Treated for Advanced Lung Cancer with Gefitinib Jpn. J. Clin. Oncol., November 7, 2009; (2009) hyp141v1. [Abstract] [Full Text] [PDF]

				D. Surguladze, D. Deevi, N. Claros, E. Corcoran, S. Wang, M. J. Plym, Y. Wu, J. Doody, D. J. Mauro, L. Witte, et al. Tumor Necrosis Factor-{alpha} and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice Cancer Res., July 15, 2009; 69(14): 5643 - 5647. [Abstract] [Full Text] [PDF]

				J. A. Burns, Y. Li, C. A. Cheney, Y. Ou, L. L. Franlin-Pfeifer, N. Kuklin, and Z.-Q. Zhang Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues J. Histochem. Cytochem., March 1, 2009; 57(3): 257 - 264. [Abstract] [Full Text] [PDF]

				K. Yonesaka, K. Zejnullahu, N. Lindeman, A. J. Homes, D. M. Jackman, F. Zhao, A. M. Rogers, B. E. Johnson, and P. A. Janne Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers Clin. Cancer Res., November 1, 2008; 14(21): 6963 - 6973. [Abstract] [Full Text] [PDF]

				C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6277 - 6283. [Abstract] [Full Text] [PDF]

				E. Eiling, M. Brandt, T. Schwarz, and A. Hauschild Pimecrolimus: A Novel Treatment for Cetuximab-Induced Papulopustular Eruption Arch Dermatol, September 1, 2008; 144(9): 1236 - 1238. [Full Text] [PDF]

				E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, G. Sala, S. Cedres, S. Peralta, H. Maacke, D. Foernzler, et al. A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy Clin. Cancer Res., June 15, 2008; 14(12): 3867 - 3874. [Abstract] [Full Text] [PDF]

				A. P. Brown, R. W. Dunstan, C. L. Courtney, K. A. Criswell, and M. J. Graziano Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor Toxicol Pathol, April 1, 2008; 36(3): 410 - 419. [Abstract] [Full Text] [PDF]

				J. A. Engelman, K. Zejnullahu, C.-M. Gale, E. Lifshits, A. J. Gonzales, T. Shimamura, F. Zhao, P. W. Vincent, G. N. Naumov, J. E. Bradner, et al. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib Cancer Res., December 15, 2007; 67(24): 11924 - 11932. [Abstract] [Full Text] [PDF]

				K. J Randall and J. R. Foster The Demonstration of Immunohistochemical Biomarkers in Methyl Methacrylate-Embedded Plucked Human Hair Follicles Toxicol Pathol, December 1, 2007; 35(7): 952 - 957. [Abstract] [Full Text] [PDF]

				M. Loprevite, M. Tiseo, M. Chiaramondia, M. Capelletti, C. Bozzetti, B. Bortesi, N. Naldi, R. Nizzoli, P. Dadati, A. Kunkl, et al. Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non Small Cell Lung Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6518 - 6526. [Abstract] [Full Text] [PDF]

				F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, and N. T. Ueno Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity Mol. Cancer Ther., August 1, 2007; 6(8): 2168 - 2177. [Abstract] [Full Text] [PDF]

				F. M. Johnson, B. Saigal, H. Tran, and N. J. Donato Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects Clin. Cancer Res., July 15, 2007; 13(14): 4233 - 4244. [Abstract] [Full Text] [PDF]

				E Calvo, S. Malik, L. Siu, G. Baillargeon, J Irish, S. Chin, P Santabarbara, J. Kreisberg, E. Rowinsky, and M Hidalgo Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer Ann. Onc., April 1, 2007; 18(4): 761 - 767. [Abstract] [Full Text] [PDF]

				M. G. Fakih, D. L. Trump, J. R. Muindi, J. D. Black, R. J. Bernardi, P. J. Creaven, J. Schwartz, M. G. Brattain, A. Hutson, R. French, et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors Clin. Cancer Res., February 15, 2007; 13(4): 1216 - 1223. [Abstract] [Full Text] [PDF]

				D. Kerob, A. Dupuy, P. Reygagne, A. Levy, P. Morel, B. A. Bernard, and C. Lebbe Facial Hypertrichosis Induced by Cetuximab, an Anti-EGFR Monoclonal Antibody Arch Dermatol, December 1, 2006; 142(12): 1656 - 1657. [Full Text] [PDF]

				A. Serrels, I. R.J. Macpherson, T.R. J. Evans, F. Y. Lee, E. A. Clark, O. J. Sansom, G. H. Ashton, M. C. Frame, and V. G. Brunton Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib Mol. Cancer Ther., December 1, 2006; 5(12): 3014 - 3022. [Abstract] [Full Text] [PDF]

				M. Levis, P. Brown, B. D. Smith, A. Stine, R. Pham, R. Stone, D. DeAngelo, I. Galinsky, F. Giles, E. Estey, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors Blood, November 15, 2006; 108(10): 3477 - 3483. [Abstract] [Full Text] [PDF]

				F. Rojo, J. Tabernero, J. Albanell, E. Van Cutsem, A. Ohtsu, T. Doi, W. Koizumi, K. Shirao, H. Takiuchi, S. R. Cajal, et al. Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma J. Clin. Oncol., September 10, 2006; 24(26): 4309 - 4316. [Abstract] [Full Text] [PDF]

				G. R. Simon, C. R. Garrett, S. C. Olson, M. Langevin, I. A. Eiseman, J. J. Mahany, C. C. Williams, R. Lush, A. Daud, P. Munster, et al. Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study Clin. Cancer Res., August 1, 2006; 12(15): 4645 - 4651. [Abstract] [Full Text] [PDF]

				J. Dimitroulakos, I. A. Lorimer, and G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin. Cancer Res., July 15, 2006; 12(14): 4426s - 4431s. [Abstract] [Full Text] [PDF]

				J. V. Heymach, M. Nilsson, G. Blumenschein, V. Papadimitrakopoulou, and R. Herbst Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4441s - 4445s. [Abstract] [Full Text] [PDF]

				M. Hidalgo, M. L. Amador, A. Jimeno, H. Mezzadra, P. Patel, A. Chan, M. E. Nielsen, A. Maitra, and S. Altiok Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. Mol. Cancer Ther., July 1, 2006; 5(7): 1895 - 1903. [Abstract] [Full Text] [PDF]

				T. L. Lee, J. Yeh, C. Van Waes, and Z. Chen Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas Mol. Cancer Ther., January 1, 2006; 5(1): 8 - 19. [Abstract] [Full Text] [PDF]

				K.-i. Fujita, Y. Ando, M. Narabayashi, T. Miya, F. Nagashima, W. Yamamoto, K. Kodama, K. Araki, H. Endo, and Y. Sasaki GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECAN Drug Metab. Dispos., December 1, 2005; 33(12): 1785 - 1790. [Abstract] [Full Text] [PDF]

				R. Hoekstra, H. Dumez, F. A.L.M. Eskens, A. van der Gaast, A. S.T. Planting, G. de Heus, K. C. Sizer, C. Ravera, S. Vaidyanathan, C. Bucana, et al. Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies Clin. Cancer Res., October 1, 2005; 11(19): 6908 - 6915. [Abstract] [Full Text] [PDF]

				N. C. Daw, W. L. Furman, C. F. Stewart, L. C. Iacono, M. Krailo, M. L. Bernstein, J. E. Dancey, R. A. Speights, S. M. Blaney, J. M. Croop, et al. Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study J. Clin. Oncol., September 1, 2005; 23(25): 6172 - 6180. [Abstract] [Full Text] [PDF]

				W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R)) Oncologist, September 1, 2005; 10(8): 579 - 589. [Abstract] [Full Text] [PDF]

				T. Mukohara, J. A. Engelman, N. H. Hanna, B. Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L. C. Cantley, et al. Differential Effects of Gefitinib and Cetuximab on Non-small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations J Natl Cancer Inst, August 17, 2005; 97(16): 1185 - 1194. [Abstract] [Full Text] [PDF]

				J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, V. Guillem, S. Gonzalez, S. Sauleda, I. Marimon, J. M. Tabernero, et al. Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer J. Clin. Oncol., August 10, 2005; 23(23): 5323 - 5333. [Abstract] [Full Text] [PDF]

				R. Perez-Soler and L. Saltz Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining? J. Clin. Oncol., August 1, 2005; 23(22): 5235 - 5246. [Abstract] [Full Text] [PDF]

				C. Montagut, J. J. Grau, R. Grimalt, J. Codony, J. Ferrando, and J. Albanell Abnormal Hair Growth in a Patient With Head and Neck Cancer Treated With the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab J. Clin. Oncol., August 1, 2005; 23(22): 5273 - 5275. [Full Text] [PDF]

				F. R. Luo, Z. Yang, H. Dong, A. Camuso, K. McGlinchey, K. Fager, C. Flefleh, D. Kan, I. Inigo, S. Castaneda, et al. Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model Clin. Cancer Res., August 1, 2005; 11(15): 5558 - 5565. [Abstract] [Full Text] [PDF]

				A Agrawal, E Gutteridge, J M W Gee, R I Nicholson, and J F R Robertson Overview of tyrosine kinase inhibitors in clinical breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S135 - S144. [Abstract] [Full Text] [PDF]

				A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells Cancer Res., May 15, 2005; 65(10): 4253 - 4260. [Abstract] [Full Text] [PDF]

				M. K. Mohamed, S. Ramalingam, Y. Lin, W. Gooding, and C. P. Belani Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer Ann. Onc., May 1, 2005; 16(5): 780 - 785. [Abstract] [Full Text] [PDF]

				R. Perez-Soler, J. P. Delord, A. Halpern, K. Kelly, J. Krueger, B. M. Sureda, J. von Pawel, J. Temel, S. Siena, D. Soulieres, et al. HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum Oncologist, May 1, 2005; 10(5): 345 - 356. [Abstract] [Full Text] [PDF]

				N. L. Spector, W. Xia, H. Burris III, H. Hurwitz, E. C. Dees, A. Dowlati, B. O'Neil, B. Overmoyer, P. K. Marcom, K. L. Blackwell, et al. Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies J. Clin. Oncol., April 10, 2005; 23(11): 2502 - 2512. [Abstract] [Full Text] [PDF]

				J. Tabernero, F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors J. Clin. Oncol., April 10, 2005; 23(11): 2521 - 2533. [Abstract] [Full Text] [PDF]

				J. Baselga and C. L. Arteaga Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459. [Abstract] [Full Text] [PDF]

				D. McKillop, E. A. Partridge, J. V. Kemp, M. P. Spence, J. Kendrew, S. Barnett, P. G. Wood, P. B. Giles, A. B. Patterson, F. Bichat, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor Mol. Cancer Ther., April 1, 2005; 4(4): 641 - 649. [Abstract] [Full Text] [PDF]

				G. Giaccone HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy Ann. Onc., April 1, 2005; 16(4): 538 - 548. [Abstract] [Full Text] [PDF]

				J. M. Cherrington Taking Biological Targeted Agents into Clinical Trial Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 23 - 29. [Full Text] [PDF]

				N. J. Meropol Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: It's Time to Get Back on Target J. Clin. Oncol., March 20, 2005; 23(9): 1791 - 1793. [Full Text] [PDF]

				S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen, and B. Halmos EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib N. Engl. J. Med., February 24, 2005; 352(8): 786 - 792. [Abstract] [Full Text] [PDF]

				D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668 Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689. [Abstract] [Full Text] [PDF]

				A. Onn, T. Isobe, W. Wu, S. Itasaka, T. Shintani, K. Shibuya, Y. Kenji, M. S. O'Reilly, I. J. Fidler, and R. S. Herbst Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8613 - 8619. [Abstract] [Full Text] [PDF]

				G.-C. Chang, T.-Y. Yang, K.-C. Chen, M.-C. Yin, R.-C. Wang, and Y.-C. Lin Complications of Therapy in Cancer Patients: CASE 1. Paronychia and Skin Hyperpigmentation Induced by Gefitinib in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., November 15, 2004; 22(22): 4646 - 4648. [Full Text] [PDF]

				V. Gregorc, G. L. Ceresoli, I. Floriani, A. Spreafico, K. B. Bencardino, V. Ludovini, L. Pistola, Z. Mihaylova, F. R. Tofanetti, M. Ferraldeschi, et al. Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6006 - 6012. [Abstract] [Full Text] [PDF]

				A. R. Tan, X. Yang, S. M. Hewitt, A. Berman, E. R. Lepper, A. Sparreboom, A. L. Parr, W. D. Figg, C. Chow, S. M. Steinberg, et al. Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor J. Clin. Oncol., August 1, 2004; 22(15): 3080 - 3090. [Abstract] [Full Text] [PDF]

				M. Wolf, H. Swaisland, and S. Averbuch Development of the Novel Biologically Targeted Anticancer Agent Gefitinib: Determining the Optimum Dose for Clinical Efficacy Clin. Cancer Res., July 15, 2004; 10(14): 4607 - 4613. [Abstract] [Full Text] [PDF]

				J. Park, B. B. Park, J. Y. Kim, S.-H. Lee, S. I. Lee, H. Y. Kim, J. H. Kim, S. H. Park, K.-E. Lee, J. O. Park, et al. Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2004; 10(13): 4383 - 4388. [Abstract] [Full Text] [PDF]

				J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896. [Full Text] [PDF]

				T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib N. Engl. J. Med., May 20, 2004; 350(21): 2129 - 2139. [Abstract] [Full Text] [PDF]

				A. Haringhuizen, H. van Tinteren, H. F. R. Vaessen, P. Baas, and N. van Zandwijk Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients Ann. Onc., May 1, 2004; 15(5): 786 - 792. [Abstract] [Full Text] [PDF]

				U. Vanhoefer, M. Tewes, F. Rojo, O. Dirsch, N. Schleucher, O. Rosen, J. Tillner, A. Kovar, A. H. Braun, T. Trarbach, et al. Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor J. Clin. Oncol., January 1, 2004; 22(1): 175 - 184. [Abstract] [Full Text] [PDF]

				M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]

				A. Santoro, R. Cavina, F. Latteri, P. A. Zucali, V. Ginanni, E. Campagnoli, B. Ferrari, E. Morenghi, V. Pedicini, M. Roncalli, et al. Activity of a specific inhibitor, gefitinib (IressaTM, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer Ann. Onc., January 1, 2004; 15(1): 33 - 37. [Abstract] [Full Text] [PDF]

				J. N. Rich, D. A. Reardon, T. Peery, J. M. Dowell, J. A. Quinn, K. L. Penne, C. J. Wikstrand, L. B. Van Duyn, J. E. Dancey, R. E. McLendon, et al. Phase II Trial of Gefitinib in Recurrent Glioblastoma J. Clin. Oncol., January 1, 2004; 22(1): 133 - 142. [Abstract] [Full Text] [PDF]

				E. Floyd and T. M. Mcshane Development and Use of Biomarkers in Oncology Drug Development Toxicol Pathol, January 1, 2004; 32(1_suppl): 106 - 115. [Abstract] [PDF]

				R. C. Cattley and B. R. Radinsky Cancer Therapeutics: Understanding the Mechanism of Action Toxicol Pathol, January 1, 2004; 32(1_suppl): 116 - 121. [Abstract] [PDF]

				M. Monti, L. L. Mancini, B. Ferrari, D. Rahal, and A. Santoro Complications of Therapy and a Diagnostic Dilemma Case: CASE 2. CUTANEOUS TOXICITY INDUCED BY CETUXIMAB J. Clin. Oncol., December 15, 2003; 21(24): 4651 - 4653. [Full Text] [PDF]

				S. R Shah, T. L Walsh, C. B Williams, and S. A Soefje Gefitinib (ZD1839, Iressa(R)): a selective epidermal growth factor receptor-tyrosine kinase inhibitor Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 151 - 160. [Abstract] [PDF]

				G. Vlahovic and J. Crawford Activation of Tyrosine Kinases in Cancer Oncologist, December 1, 2003; 8(6): 531 - 538. [Abstract] [Full Text] [PDF]

				M. L. Janmaat and G. Giaccone Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, December 1, 2003; 8(6): 576 - 586. [Abstract] [Full Text] [PDF]

				A.-M. O'Farrell, J. M. Foran, W. Fiedler, H. Serve, R. L. Paquette, M. A. Cooper, H. A. Yuen, S. G. Louie, H. Kim, S. Nicholas, et al. An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients Clin. Cancer Res., November 15, 2003; 9(15): 5465 - 5476. [Abstract] [Full Text] [PDF]

				J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro Endocrinology, November 1, 2003; 144(11): 5105 - 5117. [Abstract] [Full Text] [PDF]

				J. W. Mandell Phosphorylation State-Specific Antibodies: Applications in Investigative and Diagnostic Pathology Am. J. Pathol., November 1, 2003; 163(5): 1687 - 1698. [Abstract] [Full Text] [PDF]

				M. G. Kris, R. B. Natale, R. S. Herbst, T. J. Lynch Jr, D. Prager, C. P. Belani, J. H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, et al. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer: A Randomized Trial JAMA, October 22, 2003; 290(16): 2149 - 2158. [Abstract] [Full Text] [PDF]

				F. C. Holsinger, D. D. Doan, S. A. Jasser, E. A. Swan, J. S. Greenberg, B. A. Schiff, B. N. Bekele, M. N. Younes, C. D. Bucana, I. J. Fidler, et al. Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer Clin. Cancer Res., August 1, 2003; 9(8): 3183 - 3189. [Abstract] [Full Text] [PDF]

				F. Cappuzzo, V. Gregorc, E. Rossi, A. Cancellieri, E. Magrini, C. T. Paties, G. Ceresoli, L. Lombardo, S. Bartolini, C. Calandri, et al. Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC J. Clin. Oncol., July 15, 2003; 21(14): 2658 - 2663. [Abstract] [Full Text] [PDF]

				J. Mendelsohn and J. Baselga Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799. [Abstract] [Full Text] [PDF]

				J. Baselga Skin as a Surrogate Tissue for Pharmacodynamic End Points: Is It Deep Enough? Clin. Cancer Res., July 1, 2003; 9(7): 2389 - 2390. [Full Text] [PDF]

				M. Daneshmand, D. A. E. Parolin, H. W. Hirte, P. Major, G. Goss, D. Stewart, G. Batist, W. H. Miller Jr., S. Matthews, L. Seymour, et al. A Pharmacodynamic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Metastatic Colorectal Cancer Patients Clin. Cancer Res., July 1, 2003; 9(7): 2457 - 2464. [Abstract] [Full Text] [PDF]

				S. N. Malik, L. L. Siu, E. K. Rowinsky, L. deGraffenried, L. A. Hammond, J. Rizzo, S. Bacus, M. G. Brattain, J. I. Kreisberg, and M. Hidalgo Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients Clin. Cancer Res., July 1, 2003; 9(7): 2478 - 2486. [Abstract] [Full Text] [PDF]

				V. Grunwald and M. Hidalgo Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867. [Abstract] [Full Text] [PDF]

				S. Garattini New approaches to cancer therapy Ann. Onc., June 1, 2003; 14(6): 813 - 816. [Full Text] [PDF]

				P. M. LoRusso, R. S. Herbst, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. Kieback, S. Kaye, L. Gianni, A. Harris, et al. Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors Clin. Cancer Res., June 1, 2003; 9(6): 2040 - 2048. [Abstract] [Full Text] [PDF]

				M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies J. Clin. Oncol., May 15, 2003; 21(90100): 175s - 186. [Abstract] [Full Text] [PDF]

				C. L. Arteaga and J. Baselga Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies: Implications for Drug Development and Practice Clin. Cancer Res., May 1, 2003; 9(5): 1579 - 1589. [Full Text] [PDF]

				J. Anido, P. Matar, J. Albanell, M. Guzman, F. Rojo, J. Arribas, S. Averbuch, and J. Baselga ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells Clin. Cancer Res., April 1, 2003; 9(4): 1274 - 1283. [Abstract] [Full Text] [PDF]

				J. M. Knowlden, I. R. Hutcheson, H. E. Jones, T. Madden, J. M. W. Gee, M. E. Harper, D. Barrow, A. E. Wakeling, and R. I. Nicholson Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells Endocrinology, March 1, 2003; 144(3): 1032 - 1044. [Abstract] [Full Text] [PDF]

				K. A. Knuti, R. H. Wharton, K. L. Wharton, B. A. Chabner, T. J. Lynch Jr., and R. T. Penson Living as a Cancer Surpriser: A Doctor Tells His Story Oncologist, February 1, 2003; 8(1): 108 - 122. [Abstract] [Full Text] [PDF]

				D. B. Mendel, A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, G. Li, R. E. Schreck, T. J. Abrams, T. J. Ngai, L. B. Lee, et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship Clin. Cancer Res., January 1, 2003; 9(1): 327 - 337. [Abstract] [Full Text] [PDF]

				J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, A. Harris, T. Bjork, et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types J. Clin. Oncol., November 1, 2002; 20(21): 4292 - 4302. [Abstract] [Full Text] [PDF]

				R. S. Herbst, A.-M. Maddox, M. L. Rothenberg, E. J. Small, E. H. Rubin, J. Baselga, F. Rojo, W. K. Hong, H. Swaisland, S. D. Averbuch, et al. Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial J. Clin. Oncol., September 15, 2002; 20(18): 3815 - 3825. [Abstract] [Full Text] [PDF]

				J. Mendelsohn Targeting the Epidermal Growth Factor Receptor for Cancer Therapy J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13. [Full Text] [PDF]

				C. L. Arteaga Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression? Oncologist, August 15, 2002; 7(90004): 31 - 39. [Abstract] [Full Text] [PDF]

				J. Baselga Targeting the Epidermal Growth Factor Receptor With Tyrosine Kinase Inhibitors: Small Molecules, Big Hopes J. Clin. Oncol., May 1, 2002; 20(9): 2217 - 2219. [Full Text] [PDF]

				M. Ranson, L. A. Hammond, D. Ferry, M. Kris, A. Tullo, P. I. Murray, V. Miller, S. Averbuch, J. Ochs, C. Morris, et al. ZD1839, a Selective Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial J. Clin. Oncol., May 1, 2002; 20(9): 2240 - 2250. [Abstract] [Full Text] [PDF]